----
# Anti-HIV & Antiviral Agents
----

[Hour 1](#/hour1) |  [Hour 2](#/hour2)

Hao Chen, Ph.D


hchen@uthsc.edu Dept. Pharmacology, UTHSC

URL: http://chen42.github.io/talks/antiviral.html

Oct 25, 2018

<span id='mem'>Last modified: Thu Oct 25 07:54:57 CDT 2018</span>

---

## Conventions 
### used in this document 

* Color and style guide: 
	* Drug name: <span id="drug"> Enfuvirtide</span>
	* Links: [Clinicalkey](https://www.clinicalkey.com/#!/). 
		* You need to login via your UTHSC netid when off campus to use e-textbooks. 
		* [VPN](http://uthsc.edu/vpn/) provides a better experience. 
	* [Printable](http://chen42.github.io/talks/antiviral.html?print-pdf#/) version 
* Open link in a new browser tab:
```
CTRL click
```
* Navigate the slides:
```
<- or -> 
Space_bar 
Page_down or Page_up 
Home or End
```
* To zoom in or out:
``` 
CTRL + or CTRL -
CTRL mouse_wheel_up or CTRL mouse_wheel_down 
```

<small>
Written using [Reveal.js](https://github.com/hakimel/reveal.js) and [markdown](https://help.github.com/categories/writing-on-github/)
</small>


---

<section id="hour1">
## Agents for the treatment of virus infections 
### [Hour 1](#/hiv) 
* <a href="#/hiv">Retrovirus (HIV)</a>
	* Fusion inhibitors <span id="drug">[Enfuvirtide](#/Enfuvirtide), [Maraviroc](#/Maraviroc)</span>
	* Nucleoside reverse transcriptase inhibitors <span id="drug">[Zidovudine, Didanosine, Stavudine, Lamivudine, Abacavir, Emtricitabine](#/nrti)</span>
	* Nucleotide inhibitors <span id="drug">[Tenofovir](#/Tenofovir)</span>
	* Non-nucleoside reverse transcriptase inhibitors <span id="drug">[Nevirapine, Delavirdine, Efavirenz](#/nnrti)</span>
	* Integrase inhibitor <span id="drug">[Raltegravir, Dolutegravir, Elvitegravir](#/Integrase) </span>
	* Protease inhibitors <span id="drug">[Atazanavir, Saquinavir, Ritonavir, Lopinavir, Indinavir, Nelfinavir, Darunavir](#/pi) </span> 


---
## Objectives

1. Identify the <span style="background-color:yellow">steps in the viral replication process</span> that provide targets for antiviral therapy.

2. Understand the <span style="background-color:yellow">current guidline for HIV/AIDS treatment. </span>

3. Understand the <span style="background-color:yellow">current Initial Combination Regimens</span> for drug Naive patent.

4. Describe the mechanism of action and significant pharmacological properties of the <span style="background-color:yellow">six major classes</span> of antiretroviral (anti-HIV) agents

5. Recall the names of the drugs that act at each of the target steps in the replication process for both RNA and DNA viruses


---

<section id="hiv">
## [Human Immunodeficiency Viruses](https://www.clinicalkey.com/#!/content/book/3-s2.0-B9780323401616001716)
<img src="./images/antiviral/hiv_structural_highlight.png" width=60%>

<div id="greyText">
single, positive strand RNA 
<br>
HIV-1 widely distributed, more pathogenic | HIV-2 restricted to Central and West africa
</div>

---

## [AIDS background](https://www.clinicalkey.com/#!/content/book/3-s2.0-B978044306752550003X)

<table><tr><td width=50%>
<ol> <li> <b>Primary infection.</b> About 90% of patients develop a flu-like illness, which coincides with [seroconversion](https://aidsinfo.nih.gov/education-materials/glossary/648/seroconversion), between 2 and 4 weeks post exposure. Symptoms include, fever, night sweats, sore throat, lymphadenopathy, diarrhea. The illness is **self-limiting**.

<li> <b>Asymptomatic phase.</b> Of variable duration, from 2 to 10 years. Patients are clinically well, but infectious.

<li> <b>Acquired Immunodeficiency Syndrome (AIDS). </b>Features:
<ul><li> Constitutional disease: fever, diarrhea, weight loss, skin rashes.
	<li> Immunodeficiency: increased susceptibility to [opportunistic infections](https://www.clinicalkey.com/#!/content/book/3-s2.0-B978141603618010044X?scrollTo=%23hl0002499)	
	<li> Neurological disease: [dementia](https://www.ncbi.nlm.nih.gov/pubmed/24938216), [myelopathy](https://www.clinicalkey.com/#!/content/book/3-s2.0-B9780323287821004329?scrollTo=%23hl0000547), [peripheral neuropathy](https://www.clinicalkey.com/#!/content/book/3-s2.0-B9780323032759100121?scrollTo=%23hl0000789)	
	<li> Rare malignancies: 
		 [Kaposi sarcoma](https://www.clinicalkey.com/#!/content/book/3-s2.0-B9780323401616001431?scrollTo=%23hl0000286), 
		[oral hairy leukoplakia](https://www.clinicalkey.com/#!/content/book/3-s2.0-B9781455750177003779?scrollTo=%23hl0000151), 
		or [lymphoma](https://www.clinicalkey.com/#!/content/book/3-s2.0-B9781455746965000117?scrollTo=%23hl0001298)
</td>

<td> <img src="./images/antiviral/hiv_untreated.png" width=90%> </td>

</table>

---
## HIV in the dental clinic

### [ADA notes on HIV](https://www.ada.org/en/member-center/oral-health-topics/hiv)

* Infection with HIV predisposes people to certain oral health problems. Oral leasions are among the earliest and most common clinical signs of HIV. 
* HIV-positive patients can receive routine dental care.
* Approx. 13% of HIV positive Americans are not aware of their condition.
* Dentists and all staff with direct patient contact should follow Standard Precautions with all patients.

---

### Current [guideline](https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/10/initiation-of-antiretroviral-therapy)


#### The Initiation of Antiretroviral Therapy 

Last updated October 17, 2017


* Antiretroviral therapy (ART) is recommended for all individuals with HIV, regardless of CD4 T lymphocyte cell count, to reduce the morbidity and mortality associated with HIV infection (AI).
* ART is also recommended for individuals with HIV to prevent HIV transmission (AI).
* When initiating ART, it is important to educate patients regarding the benefits and considerations of ART, and to address strategies to optimize adherence. On a case-by-case basis, ART may be deferred because of clinical and/or psychosocial factors, but therapy should be initiated as soon as possible.

<small>Rating of Recommendations: A = Strong; B = Moderate; C = Optional </small>
<small>Rating of Evidence: I = Data from randomized controlled trials;</small>


[HAART - cART - ART](https://www.verywell.com/cart-hiv-combination-antiretroviral-therapy-48921)

---
## HIV Life Cycle 

<iframe width="600" height="400" src="https://www.youtube.com/embed/eS1GODinO8w" frameborder="0" allowfullscreen></iframe>


---
## [HIV Lifecycle](https://en.wikipedia.org/wiki/Discovery_and_development_of_HIV-protease_inhibitors#Life_cycle_of_HIV)
<img src="./images/antiviral/hiv_replication_narrow.png"  width=70%>
1. *Initiation*: attachment, penetration, uncoating
2. *Replication*: genome synthesis, RNA production, protein synthesis
3. *Release*: assembly, maturation, exit from cell
---

<section id="recommend">
### [Current Recommendations](https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/11/what-to-start)

#### treatment-naive patients

* Integrase inhibitor-based regimens 	
	* <span id="drug"> Dolutegravir / abacavir / lamivudine </span> only for HLA-B\*5701 negative patients 
	* <span id="drug"> Dolutegravir / tenofovir / emtricitabine </span> 
	* <span id="drug"> Elvitegravir / cobicistat / tenofovir / emtricitabine </span> 
	* <span id="drug"> Raltegravir / tenofovir / emtricitabine </span>
* Protease inhibitor-based regimens
	* <span id="drug"> Darunavir / ritonavir / tenofovir /emtricitabine </span> 
		
---

<section id="pi">
## Protease Inhibitors, PIs
<table> <tr><td width=40%>
[Ataza<u>navir</u> (Reyataz)](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-2795)
<br>
[Indi<u>navir</u> (Crixivan)](https://www.clinicalkey.com/#!/content/book/3-s2.0-B9780323401616001303?scrollTo=%23hl0001350)
<br>
[Nelfi<u>navir</u> (Viracept)](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-764)
<br>
[Saqui<u>navir</u> (Fortovase)](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-556)
<br>
[Fosampre<u>navir</u> (Lexiva)](https://www.clinicalkey.com/#!/content/book/3-s2.0-B9780323401616001303?scrollTo=%23hl0001368)
<br>
[<b>Rito<u>navir</u></b> (Norvir)](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-551)
<br>
[<b>Daru<u>navir</u></b> (Prezista)](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-3515)

<br>
PIs can be peptidomimetic (structural similarities to the cleavage site of HIV polyproteins) or not <span id="drug"> (nelfinavir) </span>.
</td><td>
<iframe width="560" height="400" src="https://www.youtube.com/embed/MK2r8J7SCSg?start=20&amp;stop=60" frameborder="0" allowfullscreen></iframe>
</td></tr></table>


---
## Protease Inhibitors
* Indications
	* Treatment of HIV as part of combination therapy
	* Most effective ART available
	* Effective in both acutely and chronic HIV-1 infected cells
	* Effective in monocytes and macrophages 
		* Not affected by RT inhibitors
* Mechanism of Action
	* Selective, competitive inhibitors of HIV proteases
	* Bind reversibly to protease active site
	* Prevent cleavage of polyprotein and block viral maturation
	* Early stages of HIV-1 replication cycle not affected
* Resistance
	* Each drug selects for different mutations in protease gene at level of specific codons
 
---
## Protease inhibitors

* ADME
	* Oral absorption varies
	* Bind extensively to plasma proteins
	* Renal excretion is minimal
		* No adjustments needed for renal dysfunctions
	* Metabolized by cytochrome P-450 system
		* Concurrent use of potent P-450 inducer (e.g. <span id="drug"> rifampin </span> ) leads to decreased PI concentration
	* <span style="background-color:yellow">Potent inhibitors of CYP3A4</span>
		* <span id="drug"> Ritonavir </span> used to increase (i.e. "boost") plasma concentration of other PIs except <span id="drug"> nelfinavir </span> (CYP2C19) 
		* Toxic adverse effects related to drug accumulation due to PI-mediated inhibition of hepatic P450 system
		 
note: rifampin is a bacterial RNA polymerase inhibitor

---
## protease inhibitors 
### Pharmacokinetics
|Parameter| Amprenavir | Indinavir | Nelfinavir | Ritonavir | Saquinavir | Lopinavir| Darunavir| 
|---|---|---|---|---|---|---|
|Oral bioavailability, % | 35-90 | 60-65 | 20-80|65-70|12|?| **80**<span style="background-color:yellow">&dagger;| 
|Effect of meal on AUC|&darr; 21%<br> high fat | &darr; 77% <br>high fat| &uarr; 200-300% | &uarr; 15% <br>capsule | &uarr; 600% | &uarr; 130% high fat| &uarr; 40%|
|Plasma T&frac12;elim, h| 7-11 |1.5-2| 3.5-5|3-5|7-12|6-8| 7-15| 
|Plasma protein binding, %| 90|60|98|98-99| 98|98-99| 95|
|Metabolism|CYP3A4|CYP3A4| CYP3A4 <br> CYP2C19| CYP3A4| CYP3A4| CYP3A4|<span style="background-color:yellow"> CYP3A4</span>|
|Autoinduction of metabolism|No |No|Yes|Yes|No|Yes| No| 
|Renal Excreted, % parent drug| < 3 | 11 | 1-2|3.5 |< 3|< 3| 14 |
|Inhibition of CYP3A4|++|++|++|<span style="background-color:yellow">**++++**</span>|+|+++| ++ |
||

Abbreviation: AUC, area under plasma concentration-time curve; T&frac12;elim, half-life of elimination; &uarr;, increase; &darr; decrease;
<span id="drug"> Saquinavir </span> data refer to soft-gel capsule formulation. 
<span id="drug"> Lopinavir</span> refers to coformulation with <span id="drug"> ritonavir </span> 
<br> &dagger; Coadministered with <span id="drug"> ritonavir </span> 

---

## Protease inhibitors
### Drug interactions 

* <span id="drug"> Carbamazepine</span> 
	* (treat epilepsy) lower <span id="drug"> indinavir </span> AUC and potentially other PIs
* <span id="drug"> Ketoconazole </span> 
	* (antifugal) upregulates PIs AUC
* <span id="drug"> Sildenafil </span> 
	* (vasodilator) AUC augmented by PIs
* <span id="drug"> Methadone </span>
	* (addiction treatment) AUC reduced by <span id="drug"> ritonavir / lopinavir </span> 
* Oral contraceptive AUC reduced by PIs
	* <span id="drug"> Indinavir </span> is exception


---

## Protease inhibitors
### Common <a href="#/adverse">Adverse Effects</a>
* Hyperlipidemia 
	* May be more dramatic with <span id="drug"> ritonavir </span> due to interference in lipid metabolism. 
* [Lipodystrophy](https://www.ncbi.nlm.nih.gov/PubMed/9652687)
	* Including central obesity, dorsocervical fat enlargement [(buffalo hump)](https://www.clinicalkey.com/#!/content/medline/2-s2.0-9525364), peripheral wasting, accumulation of facial fat, [lipomas](http://www.mayoclinic.org/diseases-conditions/lipoma/basics/definition/con-20024646), breast enlargement, [gynecomastia](http://www.mayoclinic.org/diseases-conditions/gynecomastia/home/ovc-20257576)
* Insulin resistance and diabetes
* Elevated liver function
* Possible increased bleeding risk in [hemophilics](https://www.clinicalkey.com/#!/content/medical_topic/21-s2.0-1014697)

---

## Protease inhibitors
### Specific Adverse Effects 
* Ritonavir 
	* Hepatotoxicity at high doses
* Indinavir
	* [Nephrolithiasis/urolithiasis](https://www.clinicalkey.com/#!/content/book/3-s2.0-B9780323280488008241): patients should drink 2 liters/day
	* [Alopecia](https://www.clinicalkey.com/#!/content/medical_topic/21-s2.0-1014848) 
* Atazanavir
	* Hyperbilirubinemia due to inhibition of UDP glucoronosyl transferase 
		* An enzyme that catalyzes bilirubin conjugation 
		* Jaundice developed in 11% patients during clinical trials

---
<section id="Darunavir">
## Darunavir

* Achieves faster virologic response than control PIs. [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/21692667) 
* Can be used to treat patients resist to other PIs. 
	* <span id="drug"> darunavir </span> displays a < 10-fold decreased susceptibility against 90% of HIV-1 isolates resistant to <span id="drug"> amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, </span> and/or <span id="drug"> tipranavir </span> . 	
* Must be used in combination in an antiviral regimen.
	* Requires an enhancer (i.e. low does <span id="drug"> ritonavir </span> or [cobicistat](https://www.ncbi.nlm.nih.gov/pubmed/26566368) )
* <a href="#/recommend">Recommended</a> for treatment-naive patients
---

## Protease Inhibitors 
### Summary 

* Indications
	* Treatment of HIV infection as part of combination therapy
* Mechanism of action 
	* Inhibition of HIV protease
* Resistance
	* Mutations of the protease gene 
		*	<span id="drug"> Indinavir, ritonavir </span> and <span id="drug"> lopinavir </span> acquire more mutations than other PIs
* ADME
	* Poor systemic bioavailability (need 'boost')
	* All PIs metabolized in liver by P450 enzymes
* Adverse effects
	* GI distress, diarrhea and vomiting
	* Increase bleeding hemophilia A or B
	* Hyperglycemia, insulin resistance and hyperlipidemia
	* Fat wasting, reaccumulation, and redistribution -- lipodystropy
* Drug interactions
	* Can be severe due to effects on P450 enzymes
 
---

<section id="Integrase">
## In<font color="darkred">tegra</font>se Inhibitor

[Ral<font color="darkred">tegra</font>vir (Isentress)](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-3572) || [Dolu<font color="darkred">tegra</font>vir (Tivicay)](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-3823) || [Elvi<font color="darkred">tegra</font>vir (Vitekta)](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-3928)

<table><tr><td>
![](./images/antiviral/hiv_integration.png)
</td> <td>
<ul>
<li>Mechanism of action
<ul>
 <li> Inhibits HIV-1 integrase enzyme <br>

 <li> Prevents insertion of viral DNA into host genome <p>
 </ul>

<li> ADME
 <ul>
 <li> Oral
 <li> Glucuronidation and by CYP3A<br>
	<li> <span id="drug"> Elvitegravir </span> is mainly metabolized by CYP3A4 <br>
	<li> Eliminated in both feces and urine <p>
</ul> 

<li> Resistance
<ul>
<li>	<span id="drug"> Dolutegravir </span> has less resistance overlap with <span id="drug"> Raltegravir </span> than does <span id="drug"> elvitegravir </span> . 
</ul>
</ul>
</td> </tr></table>

---

## Integrase Inhibitor 

* Indication
 * <a href="#/recommend">Recommended</a> for naive patients as part of combination ART 
 * Adverse effects
 * Diarrhea, nausea, headache, and fever
 * Hypersensitivity to <span id="drug"> Dolutegravir </span> include serious rash, blisters/peeling of skin, hepatitis, facial edema, angioedema, difficulty breathing, or eosinophilia.
 * Drug interactions
 * Not inducer, inhibitor or substrate of CYP3A4 (exeption: <span id="drug"> Elvitegravir </span> )
 * Metabolized by UDP glucuronosyltransferase (UGT)
 * <span id="drug"> Rifampin </span> (antibiotic) induces UGT, thus requires higher <span id="drug"> Raltegravir / Dolutegravir </span> dose
---

<section id="tepk">
## Pharmacokinetics of Integrase Inhibitors

|Parameter| Raltegravir | Dolutegravir | Elvitegravir | 
|---|---|---|---|
|Oral bioavailability, % | unknown | unknown | unknown | 
|Effect of food on AUC, % | &uarr; 46-200 | &uarr; 33-66| &uarr; 34-87 | 
|Plasma T&frac12; elim h | 9 | 14 | 8.7 |
|Plasma protein binding, % | 83 | 98.9 | 98-99 | 
|Metabolism | Glucuron| Glucoron | **CYP3A4**, Glucuron | 
|Renal excretion, parent drug, % | 32 | 31 | 6.7 |
||

 T&frac12; elim, half-life of elimination 

 [Current Recommandation](#/recommend)

---
<section id="nrti">
## [Nucleoside Reverse Transcriptase Inhibitors (NRTIs)](https://www.clinicalkey.com/#!/content/book/3-s2.0-B9781455702824000435?scrollTo=%23hl0000874)

* NRTIs
	* <span id="drug">Zidovudine</span> (Retrovir, azidothymidine [ZVD], Apo-Zidovudine, Novo-AZT)
	* <span id="drug">Stavudine</span> (Zerit, D4T)
	* <span id="drug">Didanosine</span> (Videx, dideoxyinosine, ddI)
	* <span id="drug" style="background-color:yellow">**Abacavir**</span> (Ziagen, ABC)
	* <span id="drug" style="background-color:yellow">**Lamivudine**</span> (Epivir, 3TC)
	* <span id="drug" style="background-color:yellow">**Emtricitabine**</span> (Emtriva, FTC)

---
## mechanism of action - NRTIs 
<iframe width="560" height="315" src="https://www.youtube.com/embed/cC9kyoAo1ac?start=30&list=PLMO1589WRspykVPiy6SgKi3OPKbe9b0El" frameborder="0" allowfullscreen></iframe>

---
## Mechanisms of Action - NRTIs 
* Analogs of naturally occurring [nucleosides](http://static.newworldencyclopedia.org/b/b9/Nucleotides.png)
* NRTIS are converted to their active triphosphate metabolites (i.e. a nucleotide) by <span style="background-color:yellow">host cell </span>kinases
* MoA
  * Competitive inhibitor of viral reverse transcriptase
  * Cause DNA chain termination 
  * Also inhibit host cell DNA polymerase


---
## NRTIs

* [Zidovudine](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-653) (ZDV, AZT), [Stavudine](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-573) (d4t) 
	* Analogs of pyrimidine nucleoside (T) 
	* Phosphorylated to active triphosphate forms
	* Competes with deoxythymidine triphosphate for incorporation into DNA
* [Didanosine](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-186) (ddI) 
	* Analog of purine nucleosides (A, G)
	* Active 2',3'-dideoxyadenosine 5'-triphosphate (ddATP) competes with cellular deoxyadenosine triphosphate for incorporation into viral DNA
* [Lamivudine ](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-339) (3TC), [Emtricitabine](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-2465) (FTC)
	* Analogs of pyrimidine nucleoside (C)
* [Abacavir](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-2332) (ABC)
	* Analog of purine nucleosides (G) 


---
## Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
* Indications
	* [First line treatment of HIV infection as components of ART](https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/11/what-to-start)
	* Prevent acute infection of susceptible cells
	* Little effect on cells already infected by HIV
	* <span id="drug"> Zidovudine </span> 
		* <span style="background-color:yellow">Only NRTI shown to reduce perinatal HIV transmission</a>
* Resistance
	* Drugs select for different mutations of the reverse transcriptase gene at the level of specific codons 


---
## Pharmacological Properties of NRTIs
* Good oral absorption
* Crosses blood-brain barrier
* Metabolism plays limited role in clearance 
* Excreted unchanged in urine, except:
	* <span id="drug"> Zidovudine </span> is metabolized to glucoronide
	* <span id="drug"> Abacavir </span> metabolized by alcohol dehydrogenase 
* <span id="drug"> Didanosine </span> is acid labile
	* Take 1/2 h before or 2 h after meals
	* Choose extended release formulation 
	* Others taken without regard to meals
	

---
<section id="nrtipk">
## Pharmacokinetics of NRTIs

| Parameter | Zidovudine | Lamivudine | Stavudine | Didanosine | Abacavir | Emtricitabine|
|---|---|---|---|---|---|---|
|Oral bioavailability, %| 60 | 80 | 80-90| 40 | > 70 | 75-93 | 
|Effect of meals on AUC| &darr; 24 (high fat) | &mdash; | &mdash; | &darr; 50% (acidity) | &mdash; | &mdash; | 
|Plasma t&frac12; emlim, h| 0.8-1.9 | <span style="background-color:yellow">**5-7**</span> | 1.4 | 1.0 | 0.8-1.5| <span style="background-color:yellow">**10**</span> | 
|Intracellular T&frac12;elim, triphosphate, h| 3-4 | 12 | 3.5 | 8-24 | 3 | 39| 
|Plasma protein binding, %| 20-38 | < 35 | < 5 | < 5 | 50 | < 4|
|Metabolism, %| 60-80 <br> glucuronidation | 20-30 | 80 | 50 <br>(purine metabolism) | > 80 | 9 oxidation <br> 4 glucuronidation|
|Renal excretion, %, parent drug| 15 | 70 | 40 | 20-50 | < 5 | 86|
||

AUC, area under plasma conc.-time curve; T&frac12;elim, half-life of elimination; &darr;, decrease; &mdash;, no effect 

---

## <a href="#/adverse">Adverse Effects</a> of NRTIs
* Common toxicities
	* Rash; Gastrointestinal distress
	* [Lactic acidosis](https://aidsinfo.nih.gov/education-materials/fact-sheets/22/68/hiv-and-lactic-acidosis), [hepatic steatosis](https://www.ncbi.nlm.nih.gov/pubmed/22760655) 
		* higher incidence with <span id="drug"> [stavudine or didanosine](https://www.ncbi.nlm.nih.gov/pubmed/17896969)
	* [Lipodystrophy](https://www.ncbi.nlm.nih.gov/PubMed/10509567): fat loss and/or buildup or both. 
		* Including central obesity, dorsocervical fat enlargement [(buffalo hump)](https://www.clinicalkey.com/#!/content/medline/2-s2.0-9525364), peripheral wasting, accumulation of facial fat, [lipomas](http://www.mayoclinic.org/diseases-conditions/lipoma/basics/definition/con-20024646), breast enlargement, [gynecomastia](http://www.mayoclinic.org/diseases-conditions/gynecomastia/home/ovc-20257576)
		* Most common with <span id="drug"> stavudine </span> and <span id="drug"> zidovudine </span> 

---

## <a href="#/adverse/">Adverse Effects </a>of NRTIs
 
* Unique toxicities
	* <span id="drug">Zidovudine</span>: bone marrow suppression; anemia, neutropenia; myopathy (mt DNA); 
	* <span id="drug">Didanosine</span>: pancreatitis, exacerbates peripheral neuropathy 
	* <span id="drug">Stavudine </span>: pancreatitis, exacerbates peripheral neuropathy
	* <span id="drug">Abacavir</span>: **hypersensitivity** reaction due to genetic predisposition (multi-organ autoimmune response, potentially life threatening) 
		* <span style="background-color:yellow">HLA-B\*5701	screening before starting therapy </span> [NEJM](http://www.nejm.org/doi/full/10.1056/NEJMoa0706135#t=article)
	* <span id="drug"> Emtricitabine </span>: psychiatric reactions, depression, dizziness, insomnia <span id="mem"> EmtriPSYtabine</span>

note:		* avoid co-administration with didanosine or zidovudine 


---

## Drug Interactions of NRTIs
 
* <span id="drug"> Zidovudine </span> 
	* Avoid co-administration bone marrow suppressive drugs
		* <span id="drug">Ganciclovir, interferon alpha, dapsone, flucytosine, vincristine, vinblastine</span>
* <span id="drug"> Didanosine </span>
	* Some drugs can augment the neuropathy and pancreatitis 
		* <span id="drug">Ethambutol, isoniazid, vincristine, cis-platin </span>
		* <span id="drug">Stavudine </span>
	* <span id="drug">Methadone </span> decreases plasma levels by ~60%; dosage adjustment needed

note: <span id="drug">Ganciclovir </span> increases plasma concentration; monitor for toxicity Note: <font color = grey> Antagonism with <span id="drug">Stavudine</span> [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/10882616)</font> Note: Z does not like S * Avoid use of <span id="drug"> didanosine </span> with <span id="drug"> stavudine / tenofovir </span> due to an increased toxicity risk and higher rates of early [virologic failure](https://aidsinfo.nih.gov/education-materials/glossary/879/virologic-failure) | [details](https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/15/virologic-failure)

---

## Drug Interactions of NRTIs

* <span id="drug"> Stavudine </span> 
	* Augment the neuropathy and pancreatitis with <span id="drug"> didanosine, Bortezomib </span>(myeloma), <span id="drug"> Zalcitabine </span> 
	* <span id="drug"> Zidovudine </span> inhibits the phosphorylation of <span id="drug"> stavudine </span> . For women receiving a stavudine-containing regimen, discontinue stavudine during labor while intravenous zidovudine is being administered.
* <span id="drug"> Abacavir </span> 
	* Ethanol significantly increases plasma levels (alcohol dehydrogenase)
	

---

## NRTIs 

### Summary 

* Indications 
	* First line treatment of HIV as part of ART
* Mechanism of action 
	* Inhibit viral reverse transcriptase
* Resistance 
	* Mutations in reverse transcriptase gene
* ADME 
	* Well absorbed by the GI tract; good oral bioavailability
	* Excreted unchanged by the kidney; except
		* <span id="drug"> zidovudine </span> (metabolized into glucoronide)
		* <span id="drug"> Abacavir </span> (metabolized by alcohol dehydrogenase)

---

## NRTIs 
### Summary 
* Adverse effects
	* All cause GI distress
	* Lactic acidosis with hepatic steatosis due to mitochondrial toxicity 
* Drug-Drug interactions
	* Can be severe due to synergistic effects on myelosuppression and peripheral neuropathy
 
[Current Recommendations](#/recommend)

---
<section id="Tenofovir">
## Nucleo<font color="darkorange">t</font>ide Reverse Transcriptase Inhibitor

[Teno<font color="darkorange">fo</font>vir disoproxil (Viread)](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-2477)

<span id="mem"> fo=pho=phosphate</mem>

* Properties
	* <span id="drug"> Tenofovir disoproxil </span> is a prodrug. It is hydrolyzed to release tenofovir
	* Tenofovir is an analogue of adenosine- <font color="darkorange">5'-monophosphate </font>
	* Requires two intracellular phosphorylation steps for activation
	* Weak inhibitor of mammalian DNA and mt polymerase
	* Included in many <a href="#/recommend"> first-line ART regimens</a>
	* Also indicated for <span id="bg"> hepatitis B </span>
* Mechanism of action
	* Inhibits viral reverse transcriptase by chain termination
* Resistance
	* <span id='bg'>Does not tend to select the K65R mutation when used with <span id="drug">Emtricitabine</span></span> [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23027713)
	* Cross resistance with preexisting <span id="drug"> zidovudine </span> associated mutations
	* Not affected by <span id="drug"> lamivudine-abacavir </span> associated mutations

---
## Tenofovir

* Administration
	* Once daily dosing
	* Increased bioavailability taken with a high fat meal
* Metabolism
	* Substrate of P-glycoprotein 
	* Not substrate for P450
	* T&frac12; = 17 h 
* <a href="#/adverse">Adverse effect </a>
	* Most common: nausea, vomiting, diarrhea, [flatulence](https://www.clinicalkey.com/#!/content/book/3-s2.0-B9781455770052000676?scrollTo=%23hl0000349), abdominal pain, dyspepsia, and anorexia with weight loss
	* Increases <span id="drug"> didanosine </span> concentration: pancreatitis and neuropathy
	* CNS: depression, anxiety, headache
	* Hepatotoxicity: elevated hepatic enzymes 
	* Exacerbates renal impairment 


---
## tenofovir disoproxil and emtricitabine
### (Truvada)

* Better than Abacavir-Lamivudine for initial therapy 
	* Extending time to [virologic failure](https://aidsinfo.nih.gov/education-materials/glossary/879/virologic-failure) [(details)](https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/15/virologic-failure) and first adverse event 
	* [NEJM Dec 3 2009](https://www.ncbi.nlm.nih.gov/pubmed/?term=19952143)
* Effective as antiretroviral <span id='bg'>chemoprophylaxis </span>before exposure
	* [NEJM Dec 30 2010](https://www.ncbi.nlm.nih.gov/pubmed/21091279)
* <a href="#/recommend">Recommended for treatment naive patients</a>

---

<section id="nnrti">
## Non Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

[Delavirdine (Rescriptor)](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-700)
 || [Nevirapine (Viramune)](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-432)
|| [Efavirenz (Sustiva)](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-2244)

* Indications
	* HIV-1 infections
		* Do not have significant activity against HIV-2
* Mechanism of action
	* Bind directly to a hydrophobic pocket of the reverse transcriptase 
	* Induce conformational change in active site and block enzyme activity
	* Do not require intracellular phosphorylation for activity
* Resistance
	* Resistant HIV emerges rapidly when used as monotherapy.
	* Each drug selects for different mutations of the RT gene at the level of specific codons. 

---

## NNRTIs

<iframe width="560" height="315" src="https://www.youtube.com/embed/RUUyd5bE9vQ?start=93&stop=150" frameborder="0" allowfullscreen></iframe>

---

## NNRTIs

* ADME
	* Excellent oral absorption.
	* Highly bound to plasma proteins.
	* Metabolized by the cytochrome P-450 system
		* Drug interactions are significant
	* Excreted through the urines as glucuronide conjugates. 
	* <span id="drug"> Delavirdine </span>: CYP3A4 inhibitor
		* Increases PIs, rifabutin, clarithromycin, methadone and ethinyl estradiol plasma levels
	* <span id="drug"> Efavirenz </span> and <span id="drug"> Nevirapine </span>: CYP3A4 inducer
		* Reduces PIs, rifabutin, clarithromycin, methadone and ethinyl estradiol plasma levels

---

## NNRTIs Pharmacokinetics

|Parameter| DELAVIRDINE | NEVIRAPINE\* | EFAVIRENZ\*| 
|---|---|---|---|
|Oral bioavailability, % | 85 | 90 | 50 | 
|Plasma T&frac12; elim h | 2-11 | 25-30 | 40-50|
|Plasma protein binding, % | 98 | 60 | 99| 
|Metabolism | Hepatic | Hepatic | Hepatic | 
|Renal excretion, parent drug, % | < 3 | < 3 | < 3|
|Autoinduction of metabolism | No | Yes | Yes |
|CYP3A modulation | Inhibitor | Inducer | Inducer 
||
\* values after multible doses. T&frac12; elim, half-life of elimination 


---
## <a href="#/adverse">Adverse effects</a> of NNRTIs

* Common toxicities
	* Maculopapular rashes in the trunk and extremities
* Unique toxicities 
	* <span id="drug"> Nevirapine </span> 
		* Fever, fatigue, headache, drowsiness, nausea
		* Hepatotoxicity 	
			* elevated liver enzymes 
			* fulminant cholestatic hepatitis, hepatic necrosis, and hepatic failure
	* <span id="drug"> Efavirenz </span> 
		* Penetrate the blood brain barrier 
		* Neuropsychiatric (headache, dizziness, abnormal dreams, psychosis, suicidal ideation)
		* Teratogenic in nonhuman primates ([Pregnancy Category D](https://en.wikipedia.org/wiki/Pregnancy_category))
		* Hepatotoxicity 
 
---
## NNRTIs 
### Summary 

* Indications
	* Treatment of HIV infection as part of combination therapy
	* Not effective against HIV-2
* Mechanism of action 
	* Inhibit viral reverse transcriptase
* Resistance
	* Mutations in viral reverse transcriptase
* ADME
	* Well absorbed by the GI tract
	* Good oral bioavailability
	* Metabolized in the liver 	
	* Excreted in the urine as glucoronidated metabolites
* Adverse effects
	* All NNRTIs cause rash

---

<section id="Enfuvirtide">
## <font color="darkorange">Fu</font>sion inhibitors
[En<font color="darkorange">fu</font>vir<font color="darkorange">tide</font> (Fuzeon, T20)](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-2752)

<div id="left50"> 

<b>Structure</b> <Br>
<ul>
<li> a synthetic pep<font color="darkorange">tide</font> with [36 amino acids](https://www.drugbank.ca/drugs/DB00109). 
</ul>
<p>

<b>Mechanism of action</b><br>
<ul>
<li> Binds to [gp41](https://en.wikipedia.org/wiki/Gp41#Function) of the viral envelope; prevents conformational change and impedes the fusion of the viral and host cell membranes. 
</ul>
</p>
<b>Indications</b> <br>
<ul>
<li>Reserved as salvage therapy for treatment resistant patients. 
<li>Prophylasis after occupational HIV exposure. 
<li>Not part of 1st line ART (due to the self-injection method, injection site reaction, and high cost). 
</ul>
</div>

<div id="right50">
![](./images/antiviral/coreceptor.jpg)
[video](https://youtu.be/eS1GODinO8w?t=34s)
</div>	
<div id="full"> 

</div>

---
## Enfuvirtide 
* [ADME](https://en.wikipedia.org/wiki/ADME)
	* Administered subcutaneously (synthetic peptide)
	* Bound to plasma protein
	* Metabolized by proteolytic hydrolysis
	* T&frac12; = 4 h 
* <a href="#/adverse">Adverse effect</a>
	* Injection-site pain or infection 
	* Pancreatitis
	* Hypersensitivity reaction (rash, fever, peripheral edema, acute respiratory distress, etc.) 
	* Initial report of increased bacterial pneumonia (but no longer significant after adjusting for monitoring duration)
* Resistance 
	* gp41 mutations may develop when drug is given at suboptimal doses as monotherapy; No cross-resistance with other HIV Agents
	* Ineffective for HIV-2


---

<section id="Maraviroc">
## Fusion inhibitors

[Maraviroc (<font color="orange">Sel</font>z<font color="darkred">entry</font>) ](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-3567)
 

<div id="right50">

![](./images/antiviral/coreceptor.jpg)

</div>	

<div id="left50">
**Mechanism of action** <br>

[Chemokine](https://www.ncbi.nlm.nih.gov/pubmed/7548618) receptor 5 antagonist<br>
Binds to CCR5 co-receptor<br>
Prevents virus from entering the host cell <br>
<p> 
**ADME** <br>
	Oral<br>
	Substrate for both [CYP3A4](https://en.wikipedia.org/wiki/CYP3A4#Function) and [P-glycoprotein](https://en.wikipedia.org/wiki/P-glycoprotein) <br>
	T&frac12;=14~18 h<br>
	Both urine and feces
</div>

---

## Maraviroc (Selzentry)
 
* Indication
	* Treatment of CCR5-tropic HIV-1 (not CXCR4)
	* Coreceptor (i.e. CCR5 vs CXCR4) tropism assay must be performed 
	* In combination for patients failing other antiretroviral drugs
* <a href="#/adverse">Adverse effects</a>
	* Rash
	* Elevated hepatic enzyme, hepatitis 
	* Systemic allergic reaction, cough, fever 
* Drug interactions
	* CYP3A inhibitors or inducers
		* Reduce dosage when <span id="drug"> ritonavir </span> or <span id="drug"> cobicistat </span> is coadministered 
		* Increase dosage with <span id="drug"> efavirenz </span> 
 
---

## Antiretroviral Drug Selectivity

* NRTIs
	* Once phosphorylated by cellular kinases have greater affinity for viral reverse transcriptase than for cellular DNA polymerases.
* NNRTIs
	* Do not undergo phosphorylation
	* Have greater affinity for viral reverse transcriptase than for cellular DNA polymerases
* PIs
	* Greater affinity for HIV aspartyl protease than for human protease.
* Integrase Inhibitors
	* Much higher selectivity than other classes of anti-HIV drugs.
---
## [Current Recommendations](https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/11/what-to-start)

### treatment-naive patients

* Integrase inhibitor-based regimens 	
	* <span id="drug"> Dolutegravir / abacavir / lamivudine </span> only for HLA-B\*5701 negative patients 
	* <span id="drug"> Dolutegravir / tenofovir / emtricitabine </span> 
	* <span id="drug"> Elvitegravir / [cobicistat](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-3929) <a href="#/tepk"> <small>Why</small></a>
 / tenofovir / emtricitabine </span> 
	* <span id="drug"> Raltegravir / tenofovir / emtricitabine </span>
* Protease inhibitor-based regimens
	* <span id="drug"> Darunavir / ritonavir / tenofovir /emtricitabine </span> 
		
---
<section id="hour2">

## Agents for the treatment of virus infections 
### [Hour 2](#/hour2) 
* <a href="#/hsv">Herpes Simplex Virus</a> and Varicella Zoster Virus
	* <span id="drug">[Acyclovir, Valacyclovir](#/Acyclovir), [Tenofovir](#/Tenofovir2), [Famciclovir, Penciclovir](#/Penciclovir)</span>
* <a href="#/cmv">Cytomegalovirus</a>
	* <span id="drug">[Ganciclovir, Valganciclovir](#/Ganciclovir), [Cidofovir](#/Cidofovir), [Foscarnet](#/Foscarnet)</span>
* <a href="#/hbv">Hepatitis Virus B </a>and C
	* <span id="drug"> [Entecavir](#/Entecavir), [Adefovir](#/Adefovir), [Interferon alpha](#/Interferon), [Ribavirin](#/Ribavirin)</span>
* <a href="#/flu">Influenza Virus </a>
	* Uncoating inhibitors <span id="drug"> [Amantadine, Rimantadine](#/fluuncoating)</span>
	* Viral release inhibitors <span id="drug"> [Zanamivir, Oseltamivir](#/flurelease)</span>
 
---

## Objectives 

1. For each virus, understand the major classes of available antiviral agents.
2. Describe the mechanisms of action for HSV, CMV, and HBV antiviral agents and mechanisms of viral resistance to these agents.
3. Describe the common and unique adverse effects of the distinct classes of antiviral agents
4. Identify the significant characteristics of the anti-influenza drugs acting at viral uncoating and release

---

## Agents to treat HSV, VZV and CMV
|Virus| Disease| 
|---|---|
|[Herpes simplex virus](https://www.clinicalkey.com/#!/content/book/3-s2.0-B9780323401616001388) | herpes genitalis | 
|| herpes labialis | 
|| herpetic keratoconjunctivitis |
|| herpetic encephalitis|
|[Varicella-zoster virus](https://www.clinicalkey.com/#!/content/book/3-s2.0-B9781455775668002532) | chickenpox (varicella)|
|| shingles (herpes zostr)|
|[Cytomegalovirus](https://www.clinicalkey.com/#!/content/book/3-s2.0-B9780323401616001406) | retinitis &dagger;| 
|| esophagitis &dagger;| 
||
&dagger; most often in immunocompromised (e.g. AIDS) patients.

---

<section id="hsv">

## Herpes Simplex virus

<img src="./images/antiviral/shutterstock_hsv.png" width=60%>

<div id="greyText">
Double stranded DNA virus
</div>

---

## [Life cycle](https://www.clinicalkey.com/#!/content/book/3-s2.0-B978145573984400124X?scrollTo=%23hl0000246) of HSV

<img src="./images/antiviral/dna_virus.png" width=70%>


---
## Nucleoside Analogs and others

<table><tr><td width=40%>

<ul>
<li><span id="drug">Acyclovir</span> (Zovirax)
<li><span id="drug">Valacyclovir</span> (Valtrex)
<hr>
<li><span id="drug">Penciclovir</span> (Denavir)
<li><span id="drug">Famciclovir</span> (Famvir)
<hr>
<li><span id="drug">Ganciclovir</span> (Cytovene)
<li><span id="drug">Valganciclovir</span> (Valcyte)
<hr>
<hr>
<li><span id="drug">Cido<span id='bg'>fo</span>vir</span> (Vistide)
<li><span id="drug">Foscarnet</span> (Foscavir)
</ul>

</td><td>
<ul>
<li> Mechanism of action 
<ul><li> Inactivation of viral DNA polymerase through direct binding and competition for dNTPs.
<li> Inducing viral DNA chain termination 
</ul>
</td></tr></table>


---


## Mechanisms of Activation of [Nucleoside](http://static.newworldencyclopedia.org/b/b9/Nucleotides.png) Analogs

<img src="./images/antiviral/nucleoside_activation2.png" width=40%>

---

## Nucleoside analogues

* Drug selectivity:
	* The <span style="background-color:yellow">virus in infected cells activates the drug to an active form</span>
		* Uninfected cell does not activate drug.
	* Preferential affinity of acyclovir triphosphate for viral DNA polymerase rather than cellular enzyme. 
* Resistance: 
	* Altered viral thymidine kinase substrate specificity
	* Absence of viral thymidine kinase 
	* Mutated viral DNA polymerase 

---
<section id="Acyclovir">
## Acyclovir 
### [Valacyclovir](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-636) (L-valyl ester prodrug of acyclovir)
	

* Mechanism of action 
	* <span id="drug"> acyclovir </span> is phosphorylated intracellularly by viral thymidine kinases (TK), then by cellular kinases to the triphosphate state, which terminates DNA replication when incorported into the viral DNA. 
	* Only effective against actively replicating virus. Does not eliminate the viral genome. 
* ADME
	* <span id="drug"> acyclovir </span> has low <a href="#/hsvpk">oral bioavailability</a> (10-20%). (i.v. or topical) 
	* <span id="drug"> Valacyclovir </span> is hydrolyzed to acyclovir in intestine or liver. Increase bioavailability (3.3 - 5 X) 
	* competitive inhibition of viral DNA polymerase; chain termination. 
* Indication
	* HSV keratitis, herpes labialis, genital herpes, HSV encephalitis
	* VZV 
	* CMV-positive bone marrow transplant recipients
* Adverse effects
	* Headache, nausea, diarrhea
	* Following high IV dose
		* Reversible renal dysfunction (crystalline nephropathy)
		* Neurologic toxicity (tremors, delirium, seizures)
---
<section id="Penciclovir">

## Penciclovir
### [Famciclovir](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-240) (diacetyl ester prodrug)

* ADME
	* <span id="drug"> Penciclovir </span> is for topical application only.
	* <span id="drug"> Famciclovir </span> is oral, has longer intracellular <a href="#/hsvpk">half-life</a> than <span id="drug"> Acyclovir </span>, but with lower affinity for the viral enzyme 
	* Not a CYP450 substrate
* Mechanism of action 
	* Selective substrate of HSV VZV thymidine kinase
	* Competitive inhibition of viral DNA polymerase
* Indications
	* Alternative to Acyclovir
	* Infection of HSV, VZV. 
* Adverse effects
	* Well tolerated
	* Headaches, nausea, diarrhea

---
<section id="cmv">
## Cytomegalovirus

<img src="./images/antiviral/cmv.jpg" width=60%>

<div id="greyText">
Double stranded DNA virus
</div>

---
<section id="Ganciclovir">
## Ganciclovir
### [Valganciclovir](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-2584) (L-valyl ester prodrug)


* ADME
	* <span id="drug"> Valganciclovir </span> is hydrolyzed by esterases following oral administration to <span id="drug"> ganciclovir </span> 
* Indications
	* CMV retinitis in AIDS patients
		* Activity 100 x greater than <span id="drug"> Acyclovir </span> <span id='mem'>Gangbuster drug for a gigantic virus</span> 
	* CMV prophylaxis (e.g., liver transplant patients) 
* <a href="#/adverse">Adverse effects</a>
	* Bone marrow suppression, neutropenia, anemia, 
* Drug Interactions
	* Increase the concentration of <span id="drug"> didanosine </span> 

---

<section id="Cidofovir">
## [Cido<font color="darkorange">fo</font>vir](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-125)

<span id="mem">fo=pho=phospho=nucleotide</span>

* Mechanism of action 
	* Cytidine nucleo<font color="darkorange">t</font>ide analog
	* Not phosphorylated by viral TK
	* Inhibits herpevirus DNA polymerase >> human DNA polymerase
	* Induce DNA fragmentation and Caspase-3 activity
* ADME	
	* <a href="#/hsvpk">Once weekly </a> i.v. injection 
* Indications
	* <span id="drug"> Ganciclovir, foscarnet, </span> and <span id="drug"> acyclovir </span> -resistant CMV strains	
	* <span id="drug"> cidofovir </span> i.v. delays progression of CMV retinitis in HIV+ patients
* <a href="#/adverse"> Adverse effects</a>
	* Nephrotoxicity, neutropeina, ocular hypotony, alopecia
	* Potential human carcinogen
	

---
<section id="Foscarnet">
## [<font color="darkorange">Fos</font>carnet (Foscavir)](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-267)
### Non-nucleoside Anti-HSV Agent

* Mechanism of Action
	* Inorganic pyro<font color="darkorange">phos</font>phate analog
	* Inhibits HSV DNA polymerase and HIV-1 RT
	* Binds to pyrophosphate binding site of polymerase
	* Inhibits cleavage of pyrophosphate from deoxyribonucleotide triphosphate (dNTP)
	* Blocks viral DNA synthesis
* Indications
	* Nucleoside-resistant HSV, VZV, and CMV infections
	* Effective in CMV retinitis, and acyclovir and ganciclovir-resistant strains of HSV and VZV
	* Has been used as [salvage therapy](https://www.ncbi.nlm.nih.gov/PubMed/16964823) for multi-drug resistant HIV
* <a href="#/adverse">Adverse effects</a>
	* Renal failure or dysfunction 
	* Seizure, depression, confusion, and anxiety ([high CSF/plasma ratio](#/hsvpk))
	* Bone marrow suppression
	* Nausea, vomiting, and fatigue


---

<section id="hsvpk">
## Phamacokinetics of Viral DNA Replication Inhibitors 

|Parameter|Acyclovir |Famciclovir| Ganciclovir| Cidofovir | Foscarnet|
|---|---|---|---|---|---|
|Oral bioavailability| 10-20% | 65-77% | < 10% | 2-22% | 9-17%| 
|Effect of meal on AUC| &mdash; | &mdash; | &uarr; 22% High fat | &mdash; | Uncertain |
|Plasam T&frac12;elim h| 2.5-3 | 2-3 | 2-4 | 2-3 | 4-8 (initial)|
|Intracellular T&frac12; of triphosphate h| 1 | **7-20** | > 24 | **17-56** | Not applicable | 
|CSF/plasma ratio| 0.5 | Uncertain | 0.2-0.7 | Uncertain | 0.7| 
|Protein binding| 9-34% | < 20% | 1-2%| < 6%| 15%|
|Metabolism | 15% | 5% | Negligible | Negligible |Negligible|
|Renal excretion (parent drug) | **60-90%** | **70%** | **> 90%** | **> 90%** | **> 80%**| 
|Dose adjustment | CrCl < 50 (IV) <br> CrCl < 25 (PO)| CrCl < 60| CrCl < 80| Scr > 1.5mg/dl <br> CrCl < 55| CrCl < 58-67|
||
AUC, area under curve; T&frac12;, half-life of elimination: CrCL, creatinine clearance (ml/min), Scr, serum creatinine; CSF, cerebrospinal fluid

---

## Inhibitors of Viral DNA Replication 
### Summary 
* Indications
	* HSV, VZV, and CMV infections 
* Mechanism of action
	* Inhibit viral DNA polymerases
* Resistance
	* Mutations of the viral polymerase gene
	* Deficiency of viral tyrosine kinase 
* ADME
	* Bioavailability varies. 
	* Renal excretion of unmetabolized parent drug through glomerular filtration -- Adjust dose
* <a href="#/adverse">Adverse effects</a>
	* Generally well tolerated
	* Ganciclovir -- myelosuppressant and has teratogenic potential
	* Cidofovir and Foscarnet -- nephrotoxic

---
<section id="hbv">
## Hepatitis B Virus

<img src="./images/antiviral/shutterstock_hbv.png" width=50%>

<div id="greyText">
Partially double-stranded DNA virus
</div>

---

## [HBV life cycle](https://www.clinicalkey.com/#!/content/book/3-s2.0-B9780323401616001480?scrollTo=%23hl0000906)

<iframe width="800" height="600" src="https://www.youtube.com/embed/sVpiXaEMs7I?start=290" frameborder="0" allowfullscreen></iframe>

partial DNA enters nucleus -> cccDNA -> mRNA -> <span id='bg'>HBV polymerase</span> -> DNA (negative strand) -> DNA (positive strand)
---

## Anti-Hepatitis Agents

* <span id="drug">Entecavir</span> (Baraclude)
* <span id="drug">Adefovir</span> (Hepsera)
* <span id="drug">Tenofovir</span> (Viread)
* <span id="drug">Ribavirin</span> (Virazole)
* <span id="drug">Interferon alfa-2a</span> (Roferon) and -2b (Intron A)
* <span id="drug">Peginterferon alfa-2a</span> (Pegasys) and alfa-2b (PegIntron)

---
<section id="Entecavir">
## [Entecavir](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-3427) (Baraclude)

* Mechanism of action 
	* Nucleoside analog of <b>G</b>uanosine
	* Inhibits all 3 activities of HBV polymerase
		* Base priming ([GAA](https://youtu.be/sVpiXaEMs7I?t=6m12s)) [PubMed](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399241/) 
		* Reverse transcription
		* DNA synthesis of positive strand
* Indication 
	* Effective in treatment naive HBV patients
	* Equally active against <span id="drug"> lamivudine</span>-resistant HBV

---

## Entecavir

* ADME
	* Oral bioavailability is 37-80%
	* Tablets and liquid form are interchangeable
	* Absorption is affected by food (decreased <40%)
		* Take on empty stomach (2 hrs before or 2 hrs after meal)
	* Not metabolized - not substrate for CYP450
		* No dosage alteration for hepatic impairment
	* Excreted by kidneys (both glomerular filtration and tubular secretion)
		* With CrCl < 50 ml/min, dose should be modified
		* Co-administration with other drugs that reduce renal function, may increase conc of <span id="drug"> entecavir </span> or other drug

---
## Entecavir

* Adverse effects
	* Generally well tolerated
	* **HBV exacerbation upon discontinuation of treatment**
	* Elevation of hepatic enzymes may occur, lactic acidosis 
		* Monitor hepatic function for several months and re-initiate therapy if warranted
	* Most commonly reported: headache, fatigue, dizziness
---
<section id="Tenofovir2">

## Tenofovir 

* Mechanism of action
	* A nucleotide analog of adenosine monophosphate
	* First nucleotide reverse transcriptase inhibitor
	* Inhibits viral reverse transcriptase
* Resistance
	* Thymidine analogue mutations
		* Cross resistance with preexisting <span id="drug"> zidovudine</span>-associated mutations
	* Not effected by <span id="drug"> lamivudine-abacavir </span> associated mutationse
---
## Tenofovir
* Administration
	* Once daily dosing
	* Increased bioavailability taken with a meal
* Metabolism
	* Not substrate for P450
	* No adverse drug interactions with other p450 substrate drugs
* Adverse effect: 
	* Most commonly (>3%) in clinical trials: nausea, diarrhea, asthenia, headache, vomiting, flatulence, abdominal pain, and anorexia. 
	* Increase in liver enzymes
	* watch for hepatitis flare if discontinued in patients with chronic HBV infection.
---
<section id="Adefovir">
## [Ade<font color="darkorange">fo</font>vir](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-2233)(Hepsera)

* Mechanism of action 
	* Nucleo<font color="darkorange">t</font>ide analog of deoxy<font color="darkorange">ade</font>nosine monophosphate
	* Following formation of the diphosphate by cellular kinases, it inhibits HBV DNA polymerase
	* ~10-fold more active for viral DNA polymerase than for the human DNA polymerase
	* No cross resistance of <span id="drug"> lamivudine</span>-resistant HBV strains
* Indication
	* chronic hepatitis B
* ADME
	* Oral bioavailability (60%), unaffected by meals
	* Very low protein binding, <4%
	* Renal excretion -- adjust dose with renal function impairment

---

## Adefovir 

* <a href="#/adverse">Adverse Effects</a>
	* Exacerbations of hepatitis after discontinuation of treatment 
	* Nephrotoxicity 
	* Lactic acidosis/severe hepatomegaly with steatosis
* Drug Interactions
	* The combination of adefovir with <span id="drug"> lamivudine </span> showed additive anti-HBV activity
	* Increased AUC when co-administered with <span id="drug"> ibuprofen </span> 
		* Increase in bioavailability

---
<section id="Ribavirin">

## [Ribavirin](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-542)
(Copegus | Moderiba | Rebetol | RibaPak | RibaTab | Ribasphere | Virazole)

* Mechanism of action 
	* Nucleoside analog of guanosine
	* May related to increased mutation of viral DNA and leads to "**error catastrophe**"
	* Interference with synthesis of GTP
	* Increase production of cytokine
* ADME
	* Oral bioavailability increased with fatty meals, decreased with antacids
	* <span id="drug"> Ribavirin </span> triphosphate concentrates in RBC
	* Renal clearance decreased with CrCl <30

---

## Ribavirin
* Indication 
	* Treat <u>Hepatitis C</u> in combination with <span id="drug"> peginterferon alpha </span> 
	* Weight-based dosing results in a higher sustained virologic response 
	* <u>Respiratory syncytial virus</u>: aerosolized form 
	* <u>Hantaan virus</u>: intravenous 
* Adverse effects
	* Dose dependent hemolytic anemia (10-20% of patients) with systemic use
		* Extravascular hemolysis
	* Bone morrow suppression
	* Psychiatric effects: depression, insomnia, anxiety.
	* Pyrexia (fever)
	* Aerosolized form well tolerated
		* Possible mild conjunctival irritation
		* Reversible deterioration in pulmonary function
	* Teratogenic in animals

---
## Common to all the nucleoside analogs

<span id="drug">Entecavir </span> <span id="drug">Adefovir </span> <span id="drug">Tenofovir </span> <span id="drug">Telbivudine </span>

* Lactic acidosis and severe hepatomegaly with steatosis is a more common adverse effect of the nucleoside analogs in the treatment of HIV, where they are always used in combination therapy, but these effects are much <u>less</u> likely to occur with monotherapy for treatment of hepatitis B. 

* Severe acute exacerbations of hepatitis B have been reported in patients who have stopped taking the drug.

---
## Immunoregulators

* [Interferons](https://www.clinicalkey.com/#!/content/book/3-s2.0-B9780323080583000137?scrollTo=%23hl0000129) (IFNs)
	* Potent cytokines that posses antiviral, antiproliferation (antineoplastic) and immunomodulating actions
		* Activates ribonucleases to degrade viral RNA
		* Inhibition of viral replication
		* Blocks protein synthesis &mdash; inhibits translation initiation complex
	* Three major classes of human IFNs

|Interferon|Type| Receptor| Effect|
|---|---|---|--|--|
|&alpha;|Type I | IFNAR &dagger;| Antiviral|
|&beta;| Type I | IFNAR| Antiviral| 
|&gamma;|Type II| IFNGR &Dagger;|Immunomodulation|
||
<small>
 &dagger; composed of two subunits IFNAR1 and IFNAR2. &Dagger; composed of two subunits IFNGR1 and IFNGR2
 </small>
---


## Interferons 
### Antiviral effect 

* Type I has more potent antiviral effect. It can be produced in almost any cell type when it is infected with a virus. It is triggered by molecular patterns of characteristic of viral but not host components (e.g. viral 5'-triphosphorylated ssRNA and dsRNA). 
	* dsRNA is produced by positive-strand RNA viruses and DNA viruses, but not detectable by negative-strand RNA Viruses [PubMed](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1472073/)

* Interferon alpha is generally active against the following viruses <i> in vitro</i>: 
	* <span style="font-weight:normal; font-size: 0.6em"> adenovirus; coronavirus; encephalomyocarditis virus; hepatitis B virus; hepatitis C virus (HCV); hepatitis D virus; herpes simplex virus type 1; herpes simplex virus type 2; human immunodeficiency virus (HIV); papillomavirus; poliovirus; rhinovirus; vaccinia virus; varicella-zoster virus; vesicular stomatitis virus; human T-lymphotropic virus type I (HTLV-I).
</span>

* Induces immune responses, alter the expression of genes, cell surface markers, phagocytic activity, cytotoxicity, etc. 

* Exact mechanism remain unclear, but may include the induction of enzymes that interfer with key steps in the HBV life cycle, include those that degrade foreign, but not host DNA ([PubMed](https://www.ncbi.nlm.nih.gov/pubmed?term=24557838)) 
---

<section id="Interferon">
## [Interferon alpha-2a](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-2508) 
## [peginterferon alpha-2a](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-2634)

* Indications
	* Chronic HBV, HPV and HH-V8 (Kaposi sarcoma)
	* HCV 
		* <span id='bg'> <span id="drug"> peginterferon </span> in combination with <span id="drug"> Ribavirin </span></span>
* ADME
	* Administered i.m. or s.c.
	* High bioavailability
	* Proteolytic degradation in the Kidney is the main site of metabolism
	* Eliminated in the urine ( IFN-&alpha;2 T&frac12; = 5.1 h)
	* Peginterferon has much longer T&frac12; ( 80 h) 
		* IFN-&alpha;2a is no longer produced in the USA

<small>
 \* PEG = bis-monomethoxy polyethylene glycol 
 </small>
---

## Interferon alpha-2
* <a href="#/adverse">Adverse effects</a>
	* Flu-like syndrome: nausea, vomiting, anorexia
	* Bone marrow suppression (95% patients)
	* Psychiatric effects: depression, homicidal and suicidal ideation
	* Injection site reaction
	* Should not be administered during pregnancy
* Drug interactions
	* Increases in the level of many drugs:
		* <span id="drug"> theophylline </span> (for asthema) by 100% 
		* <span id="drug"> zidovudine </span> by 93%. 
	* Co-administration with <span id="drug"> didanosine </span> increases risk of hepatic failure
	* Co-administration with <span id="drug"> zidovudine </span> can increase severity of myelosuppression.
	* Additive myelosuppressive effects when combined with some anticancer agents or immunosuppressives.

---
<section id="flu">

## [Influenza virus](https://www.clinicalkey.com/#!/content/book/3-s2.0-B9781455775668002581)

<img src="./images/antiviral/shutterstock_influenza.png" width=60%>

<div id="greyText"> Single negative strand, segmented (8) RNA virus || Type A H18N10, Type B or C </div>

---

## Life cycle


<iframe width="560" height="315" src="https://www.youtube.com/embed/2RMNwLdtRhw" frameborder="0" allow="autoplay; encrypted-media" allowfullscreen></iframe>

[Life cycle review](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2794490/)
---

## Mechanism of Action of Antiinfluenza Agents

<table><tr><td>
<img src="./images/antiviral/flu.png" width=100%>
</td><td width=50%>
<ol>
<li> virus enter the cell via H spikes. In the endosome, low pH in the endosome trigger the <span id='bg'> fusion of membranes</span>.
<li> viral ribonucleoprotein and viral RNA enters the cell nucleus, replicate the viral genome. 
<li> viral RNA is also made with a <span id='bg'>sneaky trick </span>and exported into the cytoplasm.
<li> viral protein is make and virus is packaged on cell surface
<li> the <span id='bg'>N spikes cleave the H spikes</span> and releases the viron.
</ol>
</td>
</tr></table>
---

## Antiinfluenza Agents

* Uncoating inhibitors
	* <span id="drug"> Amantadine</span> (Symadine, Symmetrel)
	* <span id="drug"> Rimantadine</span> (Flumadine)
 
* Cap-dependent endonuclease inhibitor
	* <span id="drug"> Baloxavir </span> (Xofluza)

* Virus release inhibitors
	* <span id="drug"> Zanamivir</span> (Relenza)
	* <span id="drug"> Oseltamivir</span> (Tamiflu)

---

<section id="fluuncoating">

## <span id="drug"> [Amantadine](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-20) and [rimantadine](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-547)
### Inhibitors of Uncoating

Synthetic tricyclic amines

* Indications
	* Oral prophylaxis against influenza A (but not influenza B). 
	* Good alternative to vaccine in immunocompromised patients and the elderly. 
* Mechanism of action
	* Inhibit viral replication by inhibiting uncoating of the virus.
* Resistance
	* Single amino acid substitution at the level of the transmembrane region of M2.
* Adverse effects 
	* <span id="drug">Amantadine</span> can cause anorexia, nausea and in the elderly minor CNS effects such as nervousness, anxiety, insomnia and lightheadedness. 
	* <span id="drug">Rimatandine</span> has similar effects but a lower risk of CNS adverse effects.
		* it is the methy derivative of <span id="drug"> amantadine </span> .

---
<section id="flurelease">
## <span id="drug"> [Zanamivir](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-2259) and [oseltamivir](https://www.clinicalkey.com/#!/content/drug_monograph/6-s2.0-2450)
### Inhibitors of Virus Release

Sialic acid analog inhibitors of influenza A and B neuraminidase 

* Mechanism of action
	* Competitive inhibitors of influenza neuraminidase. 
* Indications
	* Effective against influenza A and B viruses.
	* Patients who have been symptomatic for no more than 48 hours. 
* Resistance
	* HA or neuraminidase mutations
* Adverse effects: 
	* Zanamivir is orally inhaled and causes nasal and throat discomfort. 
	* Oseltamivir is taken orally and can cause nausea and vomiting.

---

## <span id="drug"> Baloxavir marboxil (Xofluza) </span> 

* Approved by the [FDA on October 24, 2018](https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm624226.htm)
	* The first oral, single-dose antiviral
	* The first medicine with a novel mechanism of action to treat the flu in nearly 20 years
* ADME	
	* Effective against influenza A and B viruses
  * Initiate treatment within 48 h of symptom onset
	* A single oral dose
	* Only for those aged 12 or more (for now)
* MoA	
	* Cellular mRNA has a 5' methylated cap and a polyA tail
	* Cap-dependent endonuclease binds to the [5' methylated caps of cellular mRNAs](http://oregonstate.edu/instruction/bi314/fall11/figure_07_16a.jpg) and cleaves the cellular mRNAs' 10 to 15 nucleotides 3' to [the cap structure. This cellular capped RNA fragment is used by the viral polymerase to prime the synthesis of viral mRNA. 	
	* Baloxavir is an inhibitor of this cap-dependent endonuclease
* Adverse effects:
	* headache, diarrhea, bronchitis

---

## Characteristics of Antiinfluenza Agents

|Parameter|Amantadine|Rimantadine| Zanamivir|Oseltamivir|Baloxavir|
|---|---|---|---|---|---|
|Spectrum| A|A|A,B|A,B|A,B|
|Route|Oral|Oral|Inhaled|Oral|Oral|
|Oral bioavailability|50-90%|>90%|<5%\*|~80%||
|Effect of meals on AUC|Negligible| Negligible|Not applicable| Negligible|decrease AUC by 36%|
|Plasma T&frac12; h| 12-18|24-36|2.5-5|6-10|79|
|Protein binding, %| 67|40|<10|3|93|
|Metabolism|<10|~75|Negligible|Negligible|UGT1A3|
|Renal excretion, %| 50-90| ~25|100|95||
|Does adjustment| CrCl <80%<br>Age>65years| CrCl <10<br>Age>65years|None|CrCl<30||
\* Systemic absorption 4% to 17% after inhalation


---
<section id="adverse">
## Antiviral Drugs with Overlapping toxicities
#### Not an exhaustive list

|Bone Marrow suppression|Peripheral neuropathy|Pancreatitis| Nephrotoxicity | Hepatoxicity| Lipodystrophy |Psychiatric CNS |Fever|Alopecia|
|---|---|---|---|---|---|---|---|---|
| | | Enfuvirtide | | Maraviroc| | | Maraviroc| | 
|Zidovudine|Zidovudine Didanosine Stavudine|Didanosine Stavudine Lamivudine (children) || Stavudine Didanosine Tenofovir|Stavudine Zidovudine Didanosine Lamivudine Abacavir|Abacavir Emtricitabine Tenofovir|Zidovudine Emtricitabine|Lamivudine|
|||||Nevirapine Efavirenz ||Efavirenz|||
|||||Dolutegravir|||||
||||Indinavir |Ritonavir|Indinavir Nelfinavir Fosamprenavir Darunavir Ritonavir|||Indinavir|
|Ganciclovir Cidofovir Foscarnet|||Cidofovir Foscarnet |||Foscarnet||Cidofovir|
|Ribavirin Peginterferon alpha2a|||Adefovir|Entecavir Adefovir||Ribavirin Peginterferon alpha2a|Ribavirin|Peginterferon alpha2a|


[Abacavir](#/nrti)||
[Acyclovir](#/Acyclovir)||
[Adefovir](#/Adefovir)||
[Amantadine](#/fluuncoating)||
[Cidofovir](#/Cidofovir)||
[Darunavir](#/Darunavir)||
[Didanosine](#/nrti)||
[Dolutegravir](#/Integrase)||
[Efavirenz](#/nnrti)||
[Emtricitabine](#/nrti)||
[Enfuvirtide](#/Enfuvirtide)||
[Entecavir](#/Entecavir)||
[Fosamprenavir](#/pi)||
[Foscarnet](#/Foscarnet)||
[Ganciclovir](#/Ganciclovir)||
[Ganciclovir](#/Ganciclovir)||
[Indinavir](#/pi)||
[Lamivudine](#/nrti)||
[Maraviroc](#/Maraviroc)||
[Nelfinavir](#/pi)||
[Nevirapine](#/nnrti)||
[Oseltamivir](#/flurelease)||
[Peginterferon](#/Interferon)||
[Penciclovir](#/Penciclovir)||
[Ribavirin](#/Ribavirin)||
[Rimantadine](#/fluuncoating)||
[Ritonavir](#/pi)||
[Stavudine](#/nrti)||
[Tenofovir](#/Tenofovir)||
[Zanamivir](#/flurelease)||
[Zidovudine](#/nrti)|| 


